The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday be remembered as the beginning of a revolution in Alzheimer’s diagnosis and treatment.
Years and years of failed Alzheimer’s trials created, and then fortified, doubts about whether drugs that attacked amyloid, a brain protein linked to Alzheimer’s disease, were a valid approach to its treatment. Those doubts may have been quelled.
Create a display name to comment
This name will appear with your comment